LEADER 00932nam0-2200313---450-
001 990009509980403321
005 20120112161733.0
010   $a978-3-642-21627-5
035   $a000950998
035   $aFED01000950998
035   $a(Aleph)000950998FED01
035   $a000950998
100   $a20120112d2012----km-y0itay50------ba
101 0 $aeng
102   $aDE
105   $aa-------001yy
200 1 $aNMR methods for the investigation of structure and transport$fEdme H. Hardy
210   $aBerlin ; Heidelberg$cSpringer$d2012
215   $aXVIII, 210 p.$cill.$d25 cm
610 0 $aSpettroscopia NMR
676   $a543.087 7$v20$zita
700  1$aHardy,$bEdme Horst$0514899
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990009509980403321
952   $a60 543.0877 B 1$b13698$fFAGBC
959   $aFAGBC
996   $aNMR methods for the investigation of structure and transport$9850351
997   $aUNINA

LEADER 01505nam  2200385Ia 450 
001 9910699378103321
005 20230902162153.0
035   $a(CKB)5470000002402132
035   $a(OCoLC)499083205
035   $a(EXLCZ)995470000002402132
100   $a20100115d2009      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry and review staff$b[electronic resource] $elabeling for human prescription drug and biological products : determining established pharmacologic class for use in the highlights of prescribing information
210  1$aSilver Spring, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research ;$aRockville, MD :$cCenter for Biologics Evaluation and Research,$d[2009]
215   $a1 electronic text (7 pages)
300   $a"Good Review Practice."
300   $a"Labeling."
300   $a"October 2009."
517   $aGuidance for industry and review staff 
606   $aDrugs$xLabeling
606   $aBiologicals$xLabeling
615  0$aDrugs$xLabeling.
615  0$aBiologicals$xLabeling.
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699378103321
996   $aGuidance for industry and review staff$93444689
997   $aUNINA